Resources – Announcements
Over the last few decades, United States Drug Testing Laboratories, Inc. (USDTL), has been quietly making a huge impact on the lives of some of the most vulnerable Neonatal Intensive Care Unit (NICU) patients, newborns exposed to substances of abuse during gestation. Today USDTL announced that they are the first laboratory in the world to commercially offer newborn fentanyl testing in both meconium and umbilical cord tissue specimens.
United States Drug Testing Laboratories, Inc. (USDTL), a pioneer in newborn forensic toxicology, alcohol biomarkers, and substances of abuse testing has announced a breakthrough in measuring Phosphatidylethanol (PEth) in newborn blood.
Our market research indicates that there is a lot of concern around testing for the substance Kratom. We wanted to inform our clients that we currently offer Kratom in Urine testing as an add-on, or as stand alone test.
To help you have the best possible solutions that science can offer, we are consistently evaluating our processes to keep them ahead of the curve. As science progresses, so do our capabilities. Because of such progress, we have some important updates to the fingernail collection process.
To help you have the best possible solutions that science can offer, we are consistently evaluating our processes to keep them ahead of the curve. As science progresses, so do our capabilities. Because of such progress, we have some important updates to the meconium collection process.
Effective July 18, 2016, USDTL will be implementing a new way of reporting quantitative results. In order to satisfy accreditation requirement, the concentrations of drugs exceeding the Upper Limit of Quantification (ULOQ) for any given drug will be reported as > ULOQ (greater than ULOQ). The ULOQ will be provided.
Quantity Not Sufficient (QNS) is a result of not having a sufficient quantity (volume) of specimen to test for the panels ordered. The amount of specimen required for collection is directly related to the amount of specimen needed to screen and confirm for the panels we offer. The initial screening uses a portion of the original specimen and the confirmation testing uses another portion of the original specimen. To forensically confirm positives, means running a new test, with a new portion of the original specimen, using a different analytical technique.
We are writing to notify our clients that effective February 1, 2016, we will no longer be testing urine for antihistamines and OTC amphetamines. We apologize for any inconvenience this may cause.
We are proud to announce that we are the first laboratory in the world to be ISO/IEC 17025 accredited for drug and alcohol testing in umbilical cord, fingernail, and toenail specimens. On September 4, 2015, USDTL attained ISO/IEC 17025 accreditation showing full compliance with the international testing standards. We have received our accreditation from ANSI-ASQ National Accreditation Board, demonstrating technical competence in the field of forensic testing. The scope of our ISO/IEC 17025 accreditation encompasses all specimen types and methods of analysis utilized in our laboratory.
We are writing to notify our clients that, effective October 1, 2015, we will no longer be offering Sevoflurane as a testing option.
We are writing to notify our clients that, effective October 1, 2015, we will no longer be offering Oral Fluid specimen testing.
I am pleased to inform you that USDTL has succeeded in improving our urine assay for antihistamine drugs by reducing the cutoff from 500 ng/mL to 100 ng/mL. The improved urine assay for antihistamine drugs will be available starting August 3, 2015.
It is our first priority to deliver testing results that provide the most valuable information possible for your substance abuse testing needs. To better accomplish this duty to our clients, we are updating our policy concerning specimens that do not have sufficient volume for both preliminary testing and confirmation. Effective April 1, 2015, confirmatory tests that cannot be completed due to insufficient specimen volume will be canceled on an individual drug class and/or analyte basis. We will report confirmation results for each test for which there is sufficient volume of specimen available, giving you access to more information.
It is USDTL's mission to use the best science available to provide cutting edge tools for the detection of alcohol and substances of abuse. To better accomplish our mission, we are updating our collection procedures for fingernail specimens. Effective March 1, 2015, cosmetic treatments of any kind must be removed from fingernail specimens prior to being submitted to USDTL for testing. Specimens received with cosmetic treatments still applied to them will be rejected and will not be processed. Cosmetic treatments include artificial acrylic, gel or silk overlays; nail polish; basecoats; topcoats; hardeners; and any application to the nail that is not the natural nail material. When removing fingernail polish prior to collection, a non-ethanol based polish remover should be used.
Des Plaines, IL - United States Drug Testing Laboratory, Inc. (USDTL), a forensic laboratory specializing in drug and alcohol testing using advanced specimens, has released a new assay to detect zolpidem (Ambien®) use in fingernail and hair specimens. Previously available only in urine and oral-fluid specimens, zolpidem testing in fingernails and hair offers forensic drug testing professionals new, powerful tools to meet their drug testing needs.
USDTL has succeeded in improving their umbilical cord screening assay for buprenorphine by reducing the positive result cutoff from 1.0 ng/g down to 0.5 ng/g. The improved umbilical cord buprenorphine assay gives the best possible detection of buprenorphine exposure, making it possible to identify more newborns exposed to buprenorphine in utero.
USDTL is the first laboratory to be awarded specimens from the Virtual Repository of Dried Blood Spots, a new national database of dried blood spot specimens available for use in research.
New data from researchers at USDTL shows that propofol use can be detected in urine samples for as long as 28 days following low-dose anesthesia.
USDTL researchers will investigate the relationship between in utero alcohol exposure and epigenetics using Small Business Innovation Research funding from the National Institute on Alcohol Abuse and Alcoholism.